Intravenous pamidronate for myeloma bone disease: can the dose be lowered?

Lancet Oncol. 2010 Oct;11(10):913-4. doi: 10.1016/S1470-2045(10)70227-8.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Density Conservation Agents / administration & dosage*
  • Bone Density Conservation Agents / adverse effects
  • Bone Diseases / etiology
  • Bone Diseases / mortality
  • Bone Diseases / prevention & control*
  • Clinical Trials, Phase III as Topic
  • Diphosphonates / administration & dosage*
  • Diphosphonates / adverse effects
  • Humans
  • Infusions, Intravenous
  • Multicenter Studies as Topic
  • Multiple Myeloma / complications
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / mortality
  • Multiple Myeloma / therapy*
  • Pamidronate
  • Quality of Life
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Risk Factors
  • Stem Cell Transplantation*
  • Time Factors
  • Transplantation, Autologous
  • Treatment Outcome

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Pamidronate